223Ra-Dichloride in castration-resistant metastatic prostate cancer: improving outcomes and identifying predictors of survival in clinical practice
Open accessThe DOI matches its Crossref record; 19 of the 20 references it cites were found in a registry or an index.
Abstract
We first assessed whether the pattern of referrals to a nuclear medicine clinic improved as experience with 223 Ra-dichloride increased, and whether referral patterns affected patient outcomes, and second assessed the value of bone scintigraphy, total alkaline phosphatase (tALP) and lymphadenopathy as prognostic factors in patients receiving 223 Ra-dichloride. A total of 57 patients eligible to receive 223 Ra-dichloride over a 2-year period (March 2014 to March 2016) were retrospectively assessed and prospectively followed (median follow up 298 days). 223 Ra-Dichloride was administered at 4-week intervals for a maximum of six injections. The numbers of patients in years 1 and 2 referred in relation to extent of bone disease (EOBD) category and overall survival (OS) were determined. The prognostic factors EOBD category, baseline tALP (tALP BL ), tALP response, greatest percentage reduction in tALP from baseline in any treatment cycle (ALP max ; among patients with elevated ALP BL ), and the presence of lymphadenopathy were assessed as predictors of OS. The proportion of patients with EOBD1 was higher in year 2 than in year 1 (29% and 4%, respectively), and in year 2 there was a lower rate of symptomatic skeleton-related events, a higher proportion of patients completing six cycles, and longer (albeit nonsignificant) OS ( p = 0.55). There were significant differences in OS between EOBD4 patients and those in all other groups and between EOBD1 and EOBD3 patients ( p < 0.05). OS was longer in patients with normal tALP BL than in those with elevated tALP BL ( p = 0.01), in ALP responders than in nonresponders ( p < 0.05), and in patients without lymphadenopathy than in those with lymphadenopathy ( p = 0.29). OS was correlated with ALP max ( r 2 = 0.24). A collaborative multidisciplinary referrals pathway, together with increased experience with 223 Ra-dichloride, led to improved outcomes. In patients with elevated tALP BL , tALP dynamics may be useful for monitoring response and predicting OS. Imaging and prognostic markers may therefore be of value for individualizing 223 Ra-dichloride treatment and planning retreatment; however, further studies are required.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures








Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the phase III ALSYMPCA trial, 223Ra-dichloride demonstrated improved overall survival and delayed symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases.”
From Radiopharmaceuticals: navigating the frontier of precision medicine and therapeutic innovation (2024) · cites this paper as [87]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Median overall survival increased from 11.3 to 14.9 months, and the median time to the first symptomatic skeletal event extended from 9.8 to 15.6 months [87].”
From Radiopharmaceuticals: navigating the frontier of precision medicine and therapeutic innovation (2024) · cites this paper as [87]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“In the phase III ALSYMPCA trial, 223Ra-dichloride demonstrated improved overall survival and delayed symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases.”
From Radiopharmaceuticals: navigating the frontier of precision medicine and therapeutic innovation (2024) · cites this paper as [87]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Common adverse events included nausea, diarrhea, vomiting, and hematologic issues.”
From Radiopharmaceuticals: navigating the frontier of precision medicine and therapeutic innovation (2024) · cites this paper as [87]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Median overall survival increased from 11.3 to 14.9 months, and the median time to the first symptomatic skeletal event extended from 9.8 to 15.6 months [87].”
From Radiopharmaceuticals: navigating the frontier of precision medicine and therapeutic innovation (2024) · cites this paper as [87]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The National Comprehensive Cancer Network: Present and future directions
McGivney, W. T. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19980515)82:10+<2057::aid-cncr14>3.0.co;2-a · Cited by 16,766
Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
Parker, C., Nilsson, S., Heinrich, D., Helle, S. I., O'Sullivan, J. M., Fosså, S. D., Chodacki, A., Wiechno, P., Logue, J., Seke, M., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1213755 · Cited by 3,408
Kirby, M., Hirst, C., & Crawford, E. D. (2011) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2011.02799.x · Cited by 861
Soloway, M. S., Hardeman, S. W., Hickey, D., Todd, B., Soloway, S., Raymond, J., & Moinuddin, M. (1988) · Cancer · doi:10.1002/1097-0142(19880101)61:1<195::aid-cncr2820610133>3.0.co;2-y · Cited by 631
Halabi, S., Kelly, W. K., Ma, H., Zhou, H., Solomon, N. C., Fizazi, K., Tangen, C. M., Rosenthal, M., Petrylak, D. P., Hussain, M., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.65.7270 · Cited by 461
Current Management of Castrate-Resistant Prostate Cancer
Hotte, S. J., & Saad, F. (2010) · Current Oncology · doi:10.3747/co.v17i0.718 · Cited by 227
Basch, E., Loblaw, D. A., Oliver, T. K., Carducci, M., Chen, R. C., Frame, J. N., Garrels, K., Hotte, S., Kattan, M. W., Raghavan, D., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.8404 · Cited by 223
Sartor, O., Coleman, R. E., Nilsson, S., Heinrich, D., Helle, S. I., O’Sullivan, J. M., Vogelzang, N. J., Bruland, Ø., Kobina, S., Wilhelm, S., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx044 · Cited by 166
Biochemical markers and skeletal metastases
Demers, L. M., Costa, L., & Lipton, A. (2000) · Cancer · doi:10.1002/1097-0142(20000615)88:12+<2919::aid-cncr7>3.0.co;2-z · Cited by 161
Increase in Prostate Cancer Distant Metastases at Diagnosis in the United States
Hu, J. C., Nguyen, P. L., Mao, J., Halpern, J. A., Shoag, J. E., Wright, J. D., & Sedrakyan, A. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2016.5465 · Cited by 139
Research works printed but not linked: 3
- 16. Gayed I, Canfield S, Fanous M, Wan D, Joseph U, Amato R. Optimizing patient selection for therapy with radium 223 dichloride. J Nucl Med. 2017;57:2016-7.
- 19. Fontana A, Delmas P. Markers of bone turnover in bone metastases. Cancer. 2000;88:2952-60. · doi:10.1002/1097-0142(20000615)88:12+<2952::aid-cncr11>3.0.co;2-m
- 27. Kulkarni H, Singh A, Baum R. Differential response of bone versus lymph node metastases after Lu-177 labelled PSMA radioligand therapy in patients with metastatic castration-resistant prostate can- cer. Eur J Nucl Med Mol Imaging. 2016;43:S37.
Cited by
Development of targeted alpha particle therapy for solid tumors.
Tafreshi, N. K., Doligalski, M. L., Tichacek, C. J., Pandya, D. N., Budzevich, M. M., El-Haddad, G., Khushalani, N. I., Moros, E. G., McLaughlin, M. L., Wadas, T. J., et al. (2019) · Molecules · doi:10.3390/molecules24234314 · Cited by 157
Radiopharmaceuticals: navigating the frontier of precision medicine and therapeutic innovation
Dhoundiyal, S., Srivastava, S., Kumar, S., Singh, G., Ashique, S., Pal, R., Mishra, N., & Taghizadeh-Hesary, F. (2024) · European Journal of Medical Research · doi:10.1186/s40001-023-01627-0 · Cited by 144
Targeted Palliative Radionuclide Therapy for Metastatic Bone Pain
Manafi‐Farid, R., Masoumi, F., Divband, G., Saidi, B., Ataeinia, B., Hertel, F., Schweighofer-Zwink, G., Morgenroth, A., & Beheshti, M. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9082622 · Cited by 51
“phosphatase were reported as significant predictors of the survival [125].”
BackgroundInfluentialTian, S., Lei, Z., Gong, Z., Sun, Z., Xu, D., & Piao, M. (2020) · Cancer Cell International · doi:10.1186/s12935-020-01508-0 · Cited by 39
Biomarkers for Treatment Response in Advanced Prostate Cancer
Asif, S., & Teply, B. A. (2021) · Cancers · doi:10.3390/cancers13225723 · Cited by 36
Metadata
- Authors
- Dizdarevic, S., Jessop, M., Begley, P., Main, S., & Robinson, A.
- Affiliations
- Brighton and Sussex Medical School (GB)
- Brighton and Sussex University Hospitals NHS Trust (GB)
- Corresponding author
- Dizdarevic, Sabina
- Venue
- European Journal of Nuclear Medicine and Molecular Imaging
- Published
- 2018-07-11
- Volume
- 45
- Issue
- 13
- Pages
- 2264-2273
- ISSN
- 1619-7070 (ISSN-L)
- 1619-7089
- PMC
- PMC6208810
- OpenAlex
- W2839363354
- Cited by
- 29
- References
- 20
- Citations by year
- 2026: 1 · 2025: 6 · 2024: 3 · 2023: 3 · 2022: 3 · 2021: 5 · 2020: 5 · 2019: 3
- FWCI
- 2.45
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- Locations
- European Journal of Nuclear Medicine and Molecular Imaging (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Bayer HealthCare (N/A)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Health Sciences › Medicine › Urology › Prostate Cancer Diagnosis and Treatment
- Keywords
- radium-223, castration-resistant prostate cancer, metastatic prostate cancer, overall survival, prognostic factors, total alkaline phosphatase, bone scintigraphy, lymphadenopathy, treatment response monitoring, bone metastasis, clinical experience, personalized treatment
- MeSH terms
- Aged, Aged, 80 and over, Alkaline Phosphatase, Humans, Male, Middle Aged, Neoplasm Metastasis, Radioisotopes, Radium, Retrospective Studies, Survival Analysis, Treatment Outcome, Prostatic Neoplasms, Castration-Resistant
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: 223Ra-Dichloride in castration-resistant metastatic prostate cancer: improving outcomes and identifying predictors of survival in clinical practice. https://app.cochat.ai/papers/10.1007/s00259-018-4083-3
- The paper
- Dizdarevic, S., Jessop, M., Begley, P., Main, S., & Robinson, A. (2018). 223Ra-Dichloride in castration-resistant metastatic prostate cancer: improving outcomes and identifying predictors of survival in clinical practice. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-018-4083-3
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.